{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:05:13Z","timestamp":1793156713992,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.spen.2021.100881","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T02:05:03Z","timestamp":1616119503000},"page":"100881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Rett Syndrome: A Timely Review From Recognition to Current Clinical Approaches and Clinical Study Updates"],"prefix":"10.1016","volume":"37","author":[{"given":"Autumn S.","family":"Ivy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Standridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2021.100881_bib0001","first-page":"723","article-title":"[On an unusual brain atrophy syndrome in hyperammonemia in childhood]","volume":"116","author":"Rett","year":"1966","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.spen.2021.100881_bib0002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ana.410140412","article-title":"A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases","volume":"14","author":"Hagberg","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methylCpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0004","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.neuron.2007.10.001","article-title":"The story of Rett syndrome: From clinic to neurobiology","volume":"56","author":"Chahrour","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2021.100881_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(20)30217-9","article-title":"Advances in understanding of Rett syndrome and MECP2 duplication syndrome: Prospects for future therapies","volume":"19","author":"Sandweiss","year":"2020","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.spen.2021.100881_bib0006","unstructured":"Kaur, S. & J. Christodoulou, MECP2 disorders. In: GeneReviews(\u00ae)Adam MP, Ardinger HH, Pagon RA, et\u00a0al, eds. GeneReviews, University of Washington; 1993-2020."},{"key":"10.1016\/j.spen.2021.100881_bib0007","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev-cellbio-092910-154121","article-title":"The role of MeCP2 in the brain","volume":"27","author":"Guy","year":"2011","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.spen.2021.100881_bib0008","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(92)90610-O","article-title":"Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA","volume":"69","author":"Lewis","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100881_bib0009","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81887-5","article-title":"MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin","volume":"88","author":"Nan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100881_bib0010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.1153252","article-title":"MeCP2, a key contributor to neurological disease, activates and represses transcription","volume":"320","author":"Chahrour","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100881_bib0011","article-title":"Functions of DNA methylation: Islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0012","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/humu.23263","article-title":"RettBASE: Rett syndrome database update","volume":"38","author":"Krishnaraj","year":"2017","journal-title":"Hum Mutat"},{"key":"10.1016\/j.spen.2021.100881_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nn.3607","article-title":"Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain","volume":"17","author":"Guo","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0014","doi-asserted-by":"crossref","DOI":"10.1126\/science.1237905","article-title":"Global epigenomic reconfiguration during mammalian brain development","volume":"341","author":"Lister","year":"2013","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.spen.2021.100881_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/hmg\/11.2.115","article-title":"Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation","volume":"11","author":"Shahbazian","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0016","article-title":"MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome","volume":"112","author":"Chen","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2021.100881_bib0017","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.conb.2019.08.001","article-title":"The distinct methylation landscape of maturing neurons and its role in Rett syndrome pathogenesis","volume":"59","author":"Lavery","year":"2019","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.spen.2021.100881_bib0018","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2013.01.038","article-title":"An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders","volume":"152","author":"Baker","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100881_bib0019","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.conb.2019.07.002","article-title":"Genomic insights into MeCP2 function: A role for the maintenance of chromatin architecture","volume":"59","author":"Connolly","year":"2019","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.spen.2021.100881_bib0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fncel.2014.00236","article-title":"MeCP2 post-translational modifications: A mechanism to control its involvement in synaptic plasticity and homeostasis?","volume":"8","author":"Bellini","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0021","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/85899","article-title":"A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome","volume":"27","author":"Guy","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0022","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/85906","article-title":"Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice","volume":"27","author":"Chen","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0023","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/jnen\/64.6.537","article-title":"Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice","volume":"64","author":"Fukuda","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0024","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2009.05.001","article-title":"Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations","volume":"35","author":"Chapleau","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.spen.2021.100881_bib0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cell.2010.10.016","article-title":"A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells","volume":"143","author":"Marchetto","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100881_bib0026","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nbd.2005.07.005","article-title":"Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome","volume":"21","author":"Asaka","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.spen.2021.100881_bib0027","doi-asserted-by":"crossref","first-page":"e92169","DOI":"10.1371\/journal.pone.0092169","article-title":"GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice","volume":"9","author":"El-Khoury","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2021.100881_bib0028","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1206593","article-title":"Adult neural function requires MeCP2","volume":"333","author":"McGraw","year":"2011","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.spen.2021.100881_bib0029","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.spen.2021.100881_bib0030","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1093\/brain\/aws096","article-title":"Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome","volume":"135","author":"Robinson","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.spen.2021.100881_bib0031","first-page":"4389","article-title":"Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes","volume":"25","author":"Ross","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"Spec No 1","key":"10.1016\/j.spen.2021.100881_bib0032","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1093\/hmg\/ddi102","article-title":"MeCP2 in neurons: closing in on the causes of Rett syndrome","volume":"14","author":"Caballero","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0033","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","article-title":"Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome","volume":"70","author":"Neul","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100881_bib0034","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/jmg.2009.072553","article-title":"Updating the profile of C-terminal MECP2 deletions in Rett syndrome","volume":"47","author":"Bebbington","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jmedgenet-2013-102113","article-title":"Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome","volume":"51","author":"Cuddapah","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0036","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jmg.2006.045260","article-title":"Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X chromosome inactivation","volume":"44","author":"Archer","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0037","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/brain\/aww302","article-title":"Longitudinal course of epilepsy in Rett syndrome and related disorders","volume":"140","author":"Tarquinio","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.spen.2021.100881_bib0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2018.03.010","article-title":"The course of awake breathing disturbances across the lifespan in Rett syndrome","volume":"40","author":"Tarquinio","year":"2018","journal-title":"Brain Dev"},{"key":"10.1016\/j.spen.2021.100881_bib0039","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1172\/JCI78167","article-title":"MECP2 disorders: From the clinic to mice and back","volume":"125","author":"Lombardi","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.spen.2021.100881_bib0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/08830738050200082401","article-title":"Neuropathology of Rett syndrome","volume":"20","author":"Armstrong","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0041","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1523\/JNEUROSCI.2159-12.2012","article-title":"Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment","volume":"32","author":"Kron","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0042","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.conb.2011.06.006","article-title":"Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: Focus on Mecp2 and Met","volume":"21","author":"Shepherd","year":"2011","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.spen.2021.100881_bib0043","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hipo.20389","article-title":"The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability","volume":"18","author":"Zhang","year":"2008","journal-title":"Hippocampus"},{"key":"10.1016\/j.spen.2021.100881_bib0044","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nbd.2010.01.018","article-title":"Synaptic circuit abnormalities of motor-frontal layer 2\/3 pyramidal neurons in a mutant mouse model of Rett syndrome","volume":"38","author":"Wood","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.spen.2021.100881_bib0045","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.1019-09.2009","article-title":"Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome","volume":"29","author":"Dani","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0046","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1523\/JNEUROSCI.5966-09.2010","article-title":"Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate","volume":"30","author":"Maezawa","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0047","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1523\/JNEUROSCI.0324-09.2009","article-title":"Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions","volume":"29","author":"Maezawa","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0048","doi-asserted-by":"crossref","first-page":"18764","DOI":"10.1523\/JNEUROSCI.2657-13.2013","article-title":"Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology","volume":"33","author":"Nguyen","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0049","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1258\/ebm.2010.010261","article-title":"Experimental models of Rett syndrome based on Mecp2 dysfunction","volume":"236","author":"Calfa","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.spen.2021.100881_bib0050","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1126\/science.7907431","article-title":"Requirement for BDNF in activity-dependent survival of cortical neurons","volume":"263","author":"Ghosh","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100881_bib0051","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/35049004","article-title":"Neurotrophins as synaptic modulators","volume":"2","author":"Poo","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0052","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neuron.2005.12.027","article-title":"The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression","volume":"49","author":"Chang","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2021.100881_bib0053","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.nbd.2008.12.011","article-title":"Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations","volume":"34","author":"Larimore","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.spen.2021.100881_bib0054","doi-asserted-by":"crossref","DOI":"10.2217\/fnl.12.79","article-title":"Recent progress in Rett syndrome and MeCP2 dysfunction: Assessment of potential treatment options","volume":"8","author":"Chapleau","year":"2013","journal-title":"Future Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0055","first-page":"103","article-title":"MeCP2 in the regulation of neural activity: Rett syndrome pathophysiological perspectives","volume":"5","author":"Cuddapah","year":"2015","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"10.1016\/j.spen.2021.100881_bib0056","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0301-0082(96)00059-7","article-title":"Rett syndrome: Neurobiological changes underlying specific symptoms","volume":"51","author":"Wenk","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.spen.2021.100881_bib0057","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.neuroscience.2010.03.065","article-title":"Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain","volume":"168","author":"Maliszewska-Cyna","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.spen.2021.100881_bib0058","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature09582","article-title":"Dysfunction in GABA signaling mediates autism-like stereotypies and Rett syndrome phenotypes","volume":"468","author":"Chao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100881_bib0059","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.14199","article-title":"Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders","volume":"5","author":"Meng","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.spen.2021.100881_bib0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fphys.2019.00479","article-title":"Neuronal redox-imbalance in rett syndrome affects mitochondria as well as cytosol, and is accompanied by intensified mitochondrial O (2) consumption and ROS release","volume":"10","author":"Can","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.spen.2021.100881_bib0061","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1093\/hmg\/ddz208","article-title":"Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett syndrome","volume":"28","author":"Jagtap","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0062","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nbd.2012.06.007","article-title":"Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome","volume":"48","author":"Grosser","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.spen.2021.100881_bib0063","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tins.2015.12.008","article-title":"Rett syndrome: Crossing the threshold to clinical translation","volume":"39","author":"Katz","year":"2016","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.spen.2021.100881_bib0064","article-title":"Neurobiologically-based treatments in Rett syndrome: Opportunities and challenges","volume":"4","author":"Kaufmann","year":"2016","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.spen.2021.100881_bib0065","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1007\/s10803-020-04381-y","article-title":"Drug studies on Rett syndrome: From bench to bedside","volume":"50","author":"Gomathi","year":"2020","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.spen.2021.100881_bib0066","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tips.2016.01.003","article-title":"The sigma-1 receptor as a pluripotent modulator in living systems","volume":"37","author":"Su","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.spen.2021.100881_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172796","article-title":"ANAVEX\u00ae2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome","volume":"187","author":"Kaufmann","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.spen.2021.100881_bib0068","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/brain\/awy323","article-title":"Towards a better diagnosis and treatment of Rett syndrome: A model synaptic disorder","volume":"142","author":"Banerjee","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.spen.2021.100881_bib0069","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(16)00120-4","article-title":"Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0071","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.spen.2021.100881_bib0072","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2018.07.029","article-title":"Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome","volume":"140","author":"Vigli","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.spen.2021.100881_bib0073","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/jcbfm.2009.109","article-title":"NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats","volume":"29","author":"Lu","year":"2009","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.spen.2021.100881_bib0074","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-6-19","article-title":"NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats","volume":"6","author":"Wei","year":"2009","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.spen.2021.100881_bib0075","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.spen.2021.100881_bib0076","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100881_bib0077","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.biopsych.2015.08.018","article-title":"Chronic administration of N-Methyl-D-Aspartate receptor antagonist ketamine improves Rett syndrome phenotype","volume":"79","author":"Patrizi","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.spen.2021.100881_bib0078","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.biopsych.2016.03.1045","article-title":"N-Methyl-D-Aspartate receptors, ketamine, and Rett syndrome: Something special on the road to treatments?","volume":"79","author":"Katz","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.spen.2021.100881_bib0079","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ceb.2004.03.005","article-title":"Recent advances in X-chromosome inactivation","volume":"16","author":"Heard","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.spen.2021.100881_bib0080","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100881_bib0081","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.0610593104","article-title":"Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2","volume":"104","author":"Giacometti","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2021.100881_bib0082","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1073\/pnas.0401626101","article-title":"Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice","volume":"101","author":"Luikenhuis","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2021.100881_bib0083","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature10907","article-title":"Wild-type microglia arrest pathology in a mouse model of Rett syndrome","volume":"484","author":"Derecki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100881_bib0084","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature10214","article-title":"A role for glia in the progression of Rett's syndrome","volume":"475","author":"Lioy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100881_bib0085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.spen.2021.100881_bib0086","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mt.2012.200","article-title":"Improved survival and reduced phenotypic severity following AAV9\/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice","volume":"21","author":"Gadalla","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100881_bib0087","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100881_bib0088","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatrics Open"},{"key":"10.1016\/j.spen.2021.100881_bib0089","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0387-7604(01)00191-7","article-title":"Lamotrigine in two cases of Rett syndrome","volume":"23","author":"Kumandas","year":"2001","journal-title":"Brain Dev"},{"key":"10.1016\/j.spen.2021.100881_bib0090","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2008-1071568","article-title":"Lamotrigine in Rett syndrome","volume":"24","author":"Uldall","year":"1993","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.spen.2021.100881_bib0091","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ejpn.2015.02.007","article-title":"Antiepileptic drugs in Rett syndrome","volume":"19","author":"Pintaudi","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0092","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/088307380401900804","article-title":"Effect of topiramate on seizures and respiratory dysrhythmia in Rett syndrome","volume":"19","author":"Goyal","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0093","doi-asserted-by":"crossref","DOI":"10.1177\/0883073813508313","article-title":"Severe respiratory dysrhythmia in Rett syndrome treated with topiramate","volume":"29","author":"Krajnc","year":"2014","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0094","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajmg.1320250525","article-title":"Therapeutic effects of a ketogenic diet in Rett syndrome","volume":"1","author":"Haas","year":"1986","journal-title":"Am J Med Genet Suppl"},{"key":"10.1016\/j.spen.2021.100881_bib0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/08830738030180011801","article-title":"Ketogenic diet in Rett syndrome","volume":"18","author":"Liebhaber","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0096","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.yebeh.2009.02.038","article-title":"Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets","volume":"15","author":"Mantis","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.spen.2021.100881_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.spen.2021.100881_bib0098","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","article-title":"Cannabidiol as a suggested candidate for treatment of autism spectrum disorder","volume":"89","author":"Poleg","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.spen.2021.100881_bib0099","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/978-1-4939-9554-7_34","article-title":"Behavioral characterization of MeCP2 dysfunction-associated Rett syndrome and neuropsychiatric disorders","volume":"2011","author":"Chin","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.spen.2021.100881_bib0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.resp.2009.04.017","article-title":"Breathing disorders in Rett syndrome: Progressive neurochemical dysfunction in the respiratory network after birth","volume":"168","author":"Katz","year":"2009","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.spen.2021.100881_bib0101","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.resp.2013.06.022","article-title":"Breathing challenges in Rett Syndrome: Lessons learned from humans and animal models","volume":"189","author":"Ramirez","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.spen.2021.100881_bib0102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s11689-015-9127-4","article-title":"Anxiety-like behavior in Rett syndrome: Characteristics and assessment by anxiety scales","volume":"7","author":"Barnes","year":"2015","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.spen.2021.100881_bib0103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.braindev.2018.08.008","article-title":"Behavioral profiles in Rett syndrome: Data from the natural history study","volume":"41","author":"Buchanan","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.spen.2021.100881_bib0104","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF02098506","article-title":"Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study","volume":"68","author":"Br\u00fccke","year":"1987","journal-title":"J Neural Transm"},{"key":"10.1016\/j.spen.2021.100881_bib0105","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1073\/pnas.0912257106","article-title":"Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities","volume":"106","author":"Samaco","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2021.100881_bib0106","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/npp.2014.105","article-title":"Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome","volume":"39","author":"De Filippis","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.spen.2021.100881_bib0107","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1113\/expphysiol.2012.069872","article-title":"Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice","volume":"98","author":"Toward","year":"2013","journal-title":"Exp Physiol"},{"key":"10.1016\/j.spen.2021.100881_bib0108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pediatrneurol.2011.12.003","article-title":"Use of buspirone and fluoxetine for breathing problems in Rett syndrome","volume":"46","author":"G\u00f6kben","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2021.100881_bib0109","doi-asserted-by":"crossref","unstructured":"Ohno K, et\u00a0al: Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome. Pediatric Neurol 60:5459.e51, 2016","DOI":"10.1016\/j.pediatrneurol.2016.03.016"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909121000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909121000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:39:00Z","timestamp":1761028740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909121000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":109,"alternative-id":["S1071909121000097"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2021.100881","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rett Syndrome: A Timely Review From Recognition to Current Clinical Approaches and Clinical Study Updates","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2021.100881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100881"}}